Literature DB >> 21641482

The clinical syndrome of bilirubin-induced neurologic dysfunction.

Lois Johnson1, Vinod K Bhutani.   

Abstract

We believe that the syndrome of bilirubin-induced neurologic dysfunction [BIND] represents a spectrum of neurologic manifestations among vulnerable infants who have experienced an exposure to bilirubin of lesser degree than generally described in previous publications. Clinical neuro-motor manifestations extend to a range of subtle processing disorders with objective disturbances of visual-motor, auditory, speech, cognition, and language among infants with a previous history of moderate-to-severe hyperbilirubinemia of varied duration. Confounding effects include prematurity, hemolysis, perinatal-neonatal complications, altered bilirubin-albumin binding, severity and duration of bilirubin exposure, and the individual vulnerability of the infant related to genetic, family, social, and educational predilection, regardless of the cause of neonatal jaundice. Tools to better assess BIND specific domains of multisensory processing disorders, identified by pyschometric, audiologic, speech, language and visual-motor, and neuromotor examination would allow for prospective surveillance of infants at risk for the syndrome.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641482     DOI: 10.1053/j.semperi.2011.02.003

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  28 in total

1.  Editorial: building evidence to manage newborn jaundice worldwide.

Authors:  Vinod K Bhutani
Journal:  Indian J Pediatr       Date:  2011-12-20       Impact factor: 1.967

2.  Developmental onset of bilirubin-induced neurotoxicity involves Toll-like receptor 2-dependent signaling in humanized UDP-glucuronosyltransferase1 mice.

Authors:  Mei-Fei Yueh; Shujuan Chen; Nghia Nguyen; Robert H Tukey
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

Review 3.  A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates.

Authors:  Robert D Christensen; Hassan M Yaish; Patrick G Gallagher
Journal:  Pediatrics       Date:  2015-06       Impact factor: 7.124

4.  Frequency-following response among neonates with progressive moderate hyperbilirubinemia.

Authors:  Gabriella Musacchia; Jiong Hu; Vinod K Bhutani; Ronald J Wong; Mei-Ling Tong; Shuping Han; Nikolas H Blevins; Matthew B Fitzgerald
Journal:  J Perinatol       Date:  2019-07-01       Impact factor: 2.521

5.  Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia.

Authors:  Andreia Barateiro; Shujuan Chen; Mei-Fei Yueh; Adelaide Fernandes; Helena Sofia Domingues; João Relvas; Olivier Barbier; Nghia Nguyen; Robert H Tukey; Dora Brites
Journal:  Mol Pharmacol       Date:  2015-10-19       Impact factor: 4.436

6.  Predictors of early vocabulary growth in children born preterm and full term: A study of processing speed and medical complications.

Authors:  Virginia A Marchman; Melanie D Ashland; Elizabeth C Loi; Katherine A Adams; Anne Fernald; Heidi M Feldman
Journal:  Child Neuropsychol       Date:  2019-02-04       Impact factor: 2.500

Review 7.  Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes.

Authors:  Courtney J Wusthoff; Irene M Loe
Journal:  Semin Fetal Neonatal Med       Date:  2015-01-10       Impact factor: 3.926

8.  Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy.

Authors:  Iman Iskander; Rasha Gamaleldin; Salma El Houchi; Amira El Shenawy; Iman Seoud; Nesrin El Gharbawi; Hazem Abou-Youssef; Aleksandr Aravkin; Richard P Wennberg
Journal:  Pediatrics       Date:  2014-10-20       Impact factor: 7.124

Review 9.  Bilirubin Binding Capacity in the Preterm Neonate.

Authors:  Sanjiv B Amin
Journal:  Clin Perinatol       Date:  2016-02-28       Impact factor: 3.430

Review 10.  Movement disorders due to bilirubin toxicity.

Authors:  Jessica Rose; Rachel Vassar
Journal:  Semin Fetal Neonatal Med       Date:  2014-12-16       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.